Clinical momentum Avisi is actively advancing VisiPlate through clinical data presentations and a pivotal SAPPHIRE trial with recent 2026 financing to support expansion. This signals readiness for larger-scale partnerships and potential procurement discussions with healthcare providers and institutions evaluating glaucoma implants.

Strategic funding With a $22M funding base and recent investments from MedVenture Partners and LSGI, Avisi demonstrates strong investor confidence and financial backing for ongoing development and commercialization efforts, creating openings for co-development deals, strategic collaborations, and grant-aligned sales initiatives.

Clinical credibility Positive twelve-month clinical data at AAO events and ongoing Visiplate trial results establish credibility with key ophthalmology centers, suggesting opportunities to engage KOLs, secure site contracts, and drive hospital adoption through clinician-led endorsements.

Industry alignment Participation in prominent accelerators and incubators (JLABS, UCSF Rosenman, OC OCTANE, MedTech Innovator) indicates pathways to partnership networks, pilot programs, and potential entry points with medical device distributors and eye care systems seeking innovative glaucoma solutions.

Geographic/ops leverage R&D and manufacturing based in Pennsylvania with ongoing investor activity and a track record of recognition position Avisi to target mid-Atlantic healthcare networks and regional health systems, offering a manageable onboarding ramp for hospital-friendly procurement and service agreements.